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The neuro-steroids 3b-androstene-17a-diol (17a-AED), 3b-androstene-17b-diol (17b-AED), 3b-androstene-7a,-17b-triol (7a-AET)
and 3b-androstene-7b,-17b-triol (7b-AET) are metabolites of dehydroepiandrosterone and are produced in neuro-ectodermal
tissue. Both epimers of androstenediols (17a-AED and 17b-AED) and androstenetriols (7a-AET and 7b-AET) have markedly
different biological functions of their chemical analogue. We investigated the cytotoxic activity of these neuro-steroids on human
T98G and U251MG glioblastoma and U937 lymphoma cells. Proliferation studies showed that 17a-AED is the most potent inhibitor,
with an IC50 B15mM. For T98G glioma, 90% inhibition was achieved with 25mM of 17a-AED. Other neuro-steroids tested only
marginally suppressed cell proliferation. Reduced cell adherence and viability could be detected after 18h of 17a-AED exposure.
Treatment with 17a-AED induced a significant level of apoptosis in U937 lymphoma cells, but not in the glioma cells. Cytopathology
of 17a-AED-treated T98G cells revealed the presence of multiple cytoplasmic vacuoles. Acridine orange staining demonstrated the
formation of acidic vesicular organelles in 17a-AED-treated T98G and U251MG, which was inhibited by bafilomycin A1. These
findings indicate that 17a-AED bears the most potent cytotoxic activity of the neuro-steroids tested, and the effectiveness may
depend on the number of hydroxyls and their position on the androstene molecule. These cytotoxic effects may utilize a non-
apoptotic pathway in malignant glioma cells.
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Glioblastomas are grade IV astrocytic neoplasms derived from the
glial lineage and represent B50% of primary central nervous
system (CNS) tumours. They are essentially incurable with a
median survival of approximately 18 months after primary
diagnosis, regardless of treatment. Traditional treatment for this
disease is surgical resection accompanied by radiation and is
generally considered palliative with the 5-year survival rate of 2%
(Surawicz et al, 1998).
Nitrosourea chemotherapeutic agents are often used as adjuvant
with radiation; however, the therapeutic benefit of the inclusion of
these agents is controversial (Walker et al, 1980; Stupp and Weber,
2005a,b). The reduced efficacy of these compounds may be
attributed to their limited penetration through the blood brain
barrier, and the resistance of migrating glioblastoma cells to
apoptosis (Kemper et al, 2004; Lefranc et al, 2005). Temozolomide
is an alkylating agent that can access the CNS, and recent clinical
studies have showed that temozolomide administration combined
with radiation therapy can improve the overall survival of
malignant glioma patients (Stupp et al, 2001; Stupp and Weber,
2005a,b). Stupp and Weber (2005a,b) demonstrated that temozo-
lomide combined with radiation therapy prolonged the survival of
glioblastoma patients with a median increase in survival of 2.5
months. Despite the recent advancement in the use of temozolo-
mide in the treatment of glioblastomas, the prognosis of these
patients remains poor and there continues to be a need for the
development of effective therapies for the treatment of this disease.
Androstene steroids are produced in neuro-ectodermal tissue by
the metabolism of the common steroid dehydroepiandrosterone
(DHEA) (Lathe, 2002). The androstenes are neuro-steroids that
exist in a- and b-epimeric forms (Figure 1) and, although
chemically identical, the biological actions of the two epimers
are distinctly different. In this regard, researchers have demon-
strated that 3b androstene 17a diol (17a-AED) can inhibit the
proliferation and induce apoptosis of human U937 and HL60
lymphoma cells (Huynh and Loria, 1997; Loria, 2002). In addition,
human MDA-MB231 and ZR75-1 breast cancer cells also undergo
apoptotic cell death when treated with 17a-AED by a mechanism
that is independent of oestrogen and androgen receptors (Huynh
et al, 2000). 17a-AED does not have inhibitory or apoptotic
effects on normal cells (Loria, 2002). In contrast, the epimer, 3b
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sandrostene 17b diol (17b-AED is an enhancer of immune
regulation (Loria, 2002). In this regard, it has been shown that
17b-AED can increase host resistance to lethal infections and acute
radiation poisoning; enhance TH1 cytokine production by
immune cells and counteract hydrocortisone induced immune-
suppression (Padgett and Loria, 1994; Loria, 1997; Ben Nathan
et al, 1999; Loria et al, 2000; Padgett et al, 2000). Furthermore, a
metabolite of 17b-AED, 3b androstene 7b,1 7 b triol (7b-AET),
which has a third hydroxyl group in the b-position on the seventh
carbon atom, is significantly more immuno-potent than 17b-AED
(Loria, 2002).
In the current study, we evaluated the cytotoxic properties of
these four androstene neuro-steroids on human T98G and
U251MG malignant glioma cell lines. We have reported that 17a-
AED, but not 17b-AED, is inhibitory to human U937 lymphoma
cells (Huynh and Loria, 1997); however, this is the first
comparative investigation of the cytotoxic potential of 7a-AET
and 7b-AET. This report shows that, among these androstenes,
17a-AED is the most potent inhibitor of human glioma and
lymphoma cell proliferation. However, the cytotoxic effects of 17a-
AED on malignant glioma cells as compared to lymphoma cells
appear to be mediated by different pathways. In this regard, 17a-
AED induces apoptosis in lymphoma cells while treated glioma
cells appear to undergo an autophagic form of cell death. This is
the first report of the antiglioma effects of androstene neuro-
steroids.
MATERIALS AND METHODS
Cell lines and culture
Glioma cells were cultured in DMEM supplemented with 10% FBS
and non-essential amino acids as adherent monolayers at 371C,
passed biweekly with trypsin in the absence of antibiotics. Cell
lines were routinely screened for mycoplasma contamination
(MycoTect, Invitrogen, Carlsbad, CA, USA). All tissue culture
reagents and supplements were obtained from Invitrogen. The
human glioblastoma cell lines T98G and U251MG were maintained
by the Neuro-Oncology Research Group at Virginia Common-
wealth Medical Center (Richmond, VA, USA). The T98G and was
originally acquired from the American Type Culture Collection
(ATCC, Manasas, VA, USA), and the U251MG cell line was
obtained from the European Collection of Cell Cultures (Wiltshire,
UK). The human U937 histiocytic lymphoma cell line (Sundstrom
and Nilsson, 1976) was obtained from the ATCC and grows in
suspension.
Proliferation assay
The proliferation of tumour cells was assessed by the incorpora-
tion of
3H-TdR (Amersham Biosciences, Piscataway, NJ, USA) in a
96-well, flat-bottom tissue culture plate. T98G and U251MG glioma
cells (1 10
4well
 1) and U937 lymphoma cells (2 10
4well
 1)
were cultured in the presence of 17a-AED, 17b-AED, 7a-AET or
7b-AET (provided by Dr Loria) at concentrations ranging from
200–3mM in a final volume of 200mlwell
 1 for 3 days. Control
wells were treated with an equivalent amount of vehicle (50%
PEG400/50% ethanol). During the last 15h of culture, cells were
pulsed with 1mCi of
3H-TdR and stored at  801C. Incorporation of
3H-TdR was used as a measure of proliferation and was analysed
using a 96-well plate harvester and a beta-plate reader (Packard,
Meridien, CT, USA). Data are expressed as percent reduction in
proliferation of the mean of triplicate experimental cultures as
compared to the mean of sham-treated cultures.
Cell viability assay
A total of 5 10
5 T98G or U251MG glioma cells were seeded in a
six-well cluster plate and incubated for 6–8h, after which medium
was removed and wells were rinsed with Hank’s Balanced Salt
Solution (HBSS, Invitrogen). Fresh medium supplemented with
17a-AED or equivalent amount of vehicle was added to the cultures
at a concentration of 10mM for T98G cells and 15mM for U251MG
cells. After 18h of exposure to 17a-AED, cultures were viewed with
a phase-contrast microscope and photographed. Floating cells
were collected. Adherent cells were trypsinized, pooled with the
non-adherent cells, centrifuged and the pellet was resuspended in
phosphate-buffered saline (PBS). U937 cells were seeded at a
concentration of 4 10
5 cellsml
 1 and after 6–8h, 17a-AED
(10mM final) or vehicle was added to the cultures. After 18h, cells
were collected, pelleted and resuspended in PBS. Over 200 cells in
total were counted in each sample on a hemacytometer, and viable
live cells were distinguished from dead cells by trypan blue
exclusion. Mean values s.e. are shown.
Assay for DNA fragmentation
Tumour cells were seeded at a concentration of 1 10
5 cellswell
 1
in a six-well cluster plate and incubated for 6–8h before addition
of 17a-AED (10mM for T98G and U937; 15mM for U251MG) or
equivalent amount of vehicle. After 4 days, detached and adherent
cells were collected as previously described and washed twice with
PBS. Terminal deoxynucleotidyltransferase dUTP nick end label-
ling (TUNEL) was used for the detections of DNA cleavage in the
treated cells (APO-DIRECT, BD Biosciences, San Diego, CA, USA).
Cells were analysed on a FACSCanto flow cytometer (BD
Biosciences). Forward scatter threshold was adjusted to omit
cellular debris; 10000 events were counted and positive TUNEL
staining was read in the FL1 channel (FITC).
Western blotting
Tumour cells were seeded in a six-well cluster plate and incubated
with 17a-AED (10mM, final) or vehicle as described above. After 3
days, spent medium was collected, centrifuged and the pellet was
added back to the original cell cultures. Cells were lysed with RIPA
buffer, lysates were clarified by centrifugation and stored at  801C.
The protein concentration of the lysates was determined using a
micro BCA protein assay kit (Pierce Chemicals, Rockford, IL,
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HO
OH
OH HO
OH
OH
Figure 1 The molecular structure of 17a-AED, 17b-AED, 7a-AET and
7b-AET androstene neuro-steroids.
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sUSA). A 25mg weight of total protein was run on a 4–12%
NuPAGE MES gel (Invitrogen) and transferred to nitrocellulose
membranes. Membranes were blocked with 5% non-fat dry
milkþ0.1% Tween-20 in PBS for 1h. The membranes were
incubated overnight with rabbit polyclonal Ab specific for poly
(ADP-ribose) polymerase (PARP) or caspase 3 (both from Cell
Signaling Technology, Beverly, MA, USA) at 41C, washed with
0.1% Tween-20 in PBS and incubated with goat anti-rabbit Ab
conjugated to horseradish peroxidase (Rockland Immuno-
chemicals, Gilbertsville, PA, USA) for 1h. Immunoreactive bands
were visualized by chemiluminescence (SuperSignal, Pierce
Chemicals). The same membranes were reblotted with a mouse
anti-b-actin mAb (Sigma, St Louis, MO, USA), as described above,
and used as a loading control.
Cytopathology
For microscopic analysis, 5 10
4 T98G glioma cells were added to
each chamber of a four-chamber glass slide and incubated for 15h.
Medium was then removed and wells were gently washed with
HBSS. Fresh medium was added and supplemented with 17a-AED
for a final concentration of 10mM. After 30h, medium was
removed, wells were gently rinsed with HBSS, cultures were fixed
with 5% buffered formalin in DMEM. Chamber slides were then
subjected to routine haematoxylin and eosin staining. Cells were
viewed with a Nikon Eclipse E800 microscope and images obtained
with a Diagnostic Instruments Spot RT CCD camera.
Detection of acidic vesicular organelles
Acidic vesicular organelles (AVO) can be detected in cells by
staining with acridine orange (Traganos and Darzynkiewicz, 1994;
Paglin et al, 2001). Tumours cells were seeded into six-well cluster
plates and cultured in the presence of vehicle or 10–15mM 17a-
AED as described above, for 3 days. In some cases, bafilomycin A1
(50nM, Sigma) was added to the cultures for the last 48h. At the
end of the culture period, acridine orange (Sigma) was added to
each culture (1.0mgml
 1 final) and cells were incubated for 15min.
Total floating and adherent cells were collected; washed with PBS
and analysed on a FACSCanto flow cytometer. When excited with a
488nm laser, the nucleolus of acridine orange stained cells
fluoresces bright green which can be detected in the FL1 channel
and acidic vesicles emit a bright red fluorescence which can be
detected in the FL3 channel (Paglin et al, 2001; Kanzawa et al,
2003b). Forward scatter threshold was adjusted to omit cellular
debris and 10000 ungated events were analysed. Tumour cells
containing AVO were identified as double positive cells in the Q2
quadrant of the FL1, FL3 histogram.
Statistiscs
Statistical analysis was performed using the Student’s t-test.
Differences were considered to be significant when the calculated
P-value was less than 0.05.
RESULTS
Androstene steroids inhibit tumour cell growth and induce
cell death
In order to determine the antiproliferative potential of the
androstene neuro-steroids, human T98G glioma, U251MG glioma
and U937 lymphoma cells were cultured in the presence of 17a-
AED, 17b-AED, 7a-AET and 7b-AET at titrated doses ranging from
3–200mM, for 3 days. The results are shown in Figure 2, and
demonstrate that 17a-AED is the most potent inhibitor of these
neuro-steroids. In this regard, 17a-AED at a dose of 25mM
inhibited the proliferation of T98G glioma and U937 lymphoma
cells by 90% or greater and U251MG glioma cell proliferation was
inhibited by 80%. For each tumour, there was a significant dose
response to 17a-AED when used between 3 to 25mM. The
approximate concentration of 17a-AED to inhibit 50% of cell
proliferation (IC50) was 10mM for T98G and U937 and 15mM for
U251MG. In contrast, 17b-AED, 7a-AET and 7b-AET could only
suppress 30% or less of tumour cell proliferation at the 50mM dose,
and these antiproliferative effects modestly increased at higher
concentrations as compared to the effects of 17a-AED. Therefore,
17a-AED is significantly more effective in inhibiting malignant
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Figure 2 17a-AED is a potent inhibitor of tumour cell proliferation. (A)
T98G glioma cells, (B) U251MG glioma cells and (C) U937 lymphoma cells
were cultured for 3 days with titrated doses of 17a-AED (K); 17b-AED
(J); 7a-AET (’)o r7 b-AET (&), in a standard proliferation assay.
Incorporation of
3H-TdR was used as a measure of cell proliferation, and
the percentage in which proliferation was inhibited in the androstene
neuro-steroid-treated cultures as compared to sham-treated cultures is
indicated. A representative experiment of at least two independent
experiments is shown.
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sglioma and lymphoma cell proliferation than its chemically
identical b-epimer (17b-AED); consequentially, nonspecificity
does not appear to be an issue. Additionally, 17a-AED is also
markedly more effective than either 7a-AET or 7b-AED, and the
inhibitory effect of 17a-AED is dose dependent. Subsequent studies
focused on the cytotoxic effects of 17a-AED when used at the
approximate IC50 concentration.
In the proliferation studies above, it may be possible that 17a-
AED interferes with the ability of the glioma cells to efficiently
adhere to the tissue culture plate and form a healthy monolayer. To
address this, we incubated the glioma cells for 6–8h before adding
17a-AED to the cultures. This time period allowed the glioma cells
to firmly attach to the tissue culture plates. Vehicle or 17a-AED
(10mM) was then added to T98G cultures. The morphological
effects of the neuro-steroid on the glioma culture could be detected
as early as 8h post-treatment, and included reduced cellular
adherence and de-attachment of cells from the tissue culture plate.
Figure 3A–D show phase-contrast images of a representative T98G
culture after 18h of exposure to vehicle or 17a-AED. The effect of
17a-AED (15mM) on U251MG glioma cultures was similar (data
not shown). Immediately following photography, the viability of
the cultures was assessed by trypan blue exclusion. The results,
shown in Figure 3E, indicate that 17a-AED-treated T98G, U251MG
and U937 cultures contain a significant percentage (33.2, 17.4 and
28.4%, respectively, Pp0.01) of non-viable cells as compared to
sham-treated cultures which was p10%. Cell death in 17a-AED-
treated T98G glioma and U937 lymphoma was approximately three
times greater than of vehicle-treated cells.
17a-AED induces apoptosis of human U937 lymphoma
cells, but not T98G and U251MG glioma cells
Several standard assays for apoptosis were conducted on U937
lymphoma and the malignant glioma T98G and U251MG cells
treated with 17a-AED or vehicle for 3–4 days. Nuclear DNA
fragmentation is a morphological change that occurs in apoptotic
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Figure 3 Cytotoxic effects of 17a-AED. Tumour cells were seeded onto culture dishes and incubated for B8h before the addition of 17a-AED. After
18h of treatment, cultures were photographed and the viability of cells was determined. (A, C) T98G cells treated with vehicle or (B, D)1 0mM 17a-AED.
(E) Cell death of T98G glioma and U937 lymphoma cells treated with 10mM 17a-AED and U251MG glioma cells treated with 15mM 17a-AED. Mean values
of at least two independent experiments are shown. *P¼0.001, **Pp0.01.
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scells and is a classical feature of apoptosis (Nagata et al, 2003). A
TUNEL assay was performed on the tumour cells treated with 17a-
AED to detect DNA cleavage, which was quantified by flow
cytometry. The results are shown in Figure 4. In the U937
lymphoma cultures treated with 17a-AED, 39.4% of the cells were
TUNEL positive, indicating that these cells were apoptotic.
Furthermore, induction of apoptosis by 17a-AED treatment of
U937 lymphoma cells was dose dependent, as revealed by annexing
V staining, with an LD50 between 6.25 and 12.5mM (data not
shown). In contrast to U937 cells, only a low level, 7.7% of T98G
glioma cells treated with 17a-AED were positive for TUNEL and
the percentage of TUNEL-positive U251MG cells exposed to 17a-
AED remained at the level of sham-treated U251MG cells.
Proteolytic processing of the effector caspase 3 and PARP are
biochemical events of apoptosis and the presence of their cleavage
products are markers of this cell death pathway (Nunez et al, 1998;
Oliver et al, 1998). Western blotting was conducted using whole-
cell lysates from human U937, T98G and U251MG cells treated
with 17a-AED, to determine the extent of caspase 3 and PARP
cleavage. The results, shown in Figure 5, demonstrate that U937
lymphoma cells treated with 17a-AED have an increased level of
cleaved caspase 3 and PARP as compared to cells treated with
vehicle. In contrast, no cleavage of caspase 3 was detected in
treated T98G and U251MG malignant glioma cells, and there was
no change in background levels of PARP cleavage noted in the 17a-
AED-treated glioma cells as compared to glioma cells exposed to
vehicle. Caspase 3 cleavage and PARP processing was not detected
in U937, T98G and U251MG tumour cells exposed to 17a-AED for
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Figure 4 17a-AED treatment induces DNA fragmentation of U937 lymphoma cells. (A) U937 lymphoma cells; (B) T98G glioma cells and (C) U251MG
glioma cells were treated with vehicle (left panels) or 17a-AED (right panels). After 4 days, the degree of DNA cleavage was assessed by TUNEL staining
and used as a measure of apoptosis. Annotated numbers reflect the percentage of cells staining positive for apoptosis (x-axis, FITC-A). This experiment was
performed twice and yielded similar results.
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s24 or 48h, thereby excluding the possibility of early apoptotic cell
death in these experiments (data not shown). These results
demonstrate that 17a-AED treatment induces U937 lymphoma
cells to undergo apoptosis, which is in accordance with our
previous report (Huynh and Loria, 1997). However, the major
cytotoxic effects of 17a-AED on malignant glioma cells appear to
be mediated by a non-apoptotic pathway.
Cytopathic effects of 17a-AED on T9G8 glioma cells
Human T98G glioma cells were cultured for 30h in the presence of
vehicle or 17a-AED at a final concentration of 10mM. Analysis of
haematoxylin and eosin-stained cultures revealed significant
morphological alterations as a result of 17a-AED treatment. In
the sham-treated T98G culture (Figure 6A), glioma cells displayed
a large, pale staining nucleus containing prominent nucleoli, and
were epithelioid in appearance. Also in the control culture,
numerous mitotic figures were apparent and, in a small percentage
of cells, marginal cytoplasmic vacuolization could be noted. In the
17a-AED-treated cultures (Figures 6B and C), very few mitotic
figures were present, and a substantial number of T98G cells
contained multiple, cytoplasmic vacuoles which, in some cases,
appeared to displace the nucleus. Vacuolization was often
accompanied by the presence of small, basophilic bodies. The
presence of these vacuoles in the 17a-AED-treated T98G cells was
also detected by flow cytometry as an increase of cellular side
scatter (data not shown).
17a-AED induces autophagosome formation in malignant
glioma cells
Cytoplasmic vacuolization is a feature of certain death pathways
such as necrosis and autophagy, but not apoptosis, and the
presence of acidic vacuoles or AVO is a characteristic of
autophagic cell death (Paglin et al, 2001; Lefranc and Kiss, 2006).
Vital staining with acridine orange was used to detect the presence
of AVO in tumour cells treated with 17a-AED. The results shown
in Figure 7A indicate that more than 40% of T98G glioma cells and
only 4.0% of U937 lymphoma cells (Figure 7B) treated with the
neuro-steroid contained AVO. A high percentage of AVO was also
detected in U251 malignant glioma cells treated with 17a-AED, as
compared to sham-treated cells (data not shown). Bafilomycin A1
specifically inhibits AVO formation by blocking the fusion of
autophagosomes and lysosomes (Yamamoto et al, 1998). The
addition of bafilomycin A1 prevented the generation of AVO in
17a-AED-treated T98G glioma cells (Figure 7A) and U251MG
glioma cells (data not shown). These results suggest that 17a-AED
induces autophagic cell death in human malignant glioma cells,
but not in lymphoma cells.
DISCUSSION
The anticancer effects of DHEA have been widely investigated and
researchers have shown that treatment with DHEA can inhibit the
growth of different tumours such as colon adenocarcinoma
(Schulz et al, 1992), pancreatic carcinoma (Melvin et al, 1997)
and breast cancer (Boccuzzi et al, 1993). Additionally, DHEA
treatment has been shown to retard the onset of chemically
induced cancers such as mammary, liver and prostate carcino-
genesis in experimental rat models (Simile et al, 1995; Lubet et al,
1998; Rao et al, 1999). More recently, Yoshida et al (2003) reported
that DHEA and its metabolites have antiproliferative effects on
human hepatoma and human colonic adenocarcinoma cell lines.
The androstene steroid molecules used in this study are naturally
synthesized in neuro-ectodermal tissue by the metabolism of
DHEA, and represent a true class of neuro-steroids. In this
investigation, we examined the cytotoxic effects of chemically
identical or similar androstene derivatives on two human
malignant glioma cell lines and a human lymphoma cell line.
Our findings demonstrate that the androstene neuro-steroids can
inhibit the proliferation of these tumour cells, induce cell death,
-Actin
Caspase-3
PARP
Veh 17 Veh
T98G U251MG U937
17 17 Veh
Figure 5 Treatment with 17a-AED induces cleavage of caspase 3 and
PARP in U937 lymphoma cells, but not in T98G and U251MG glioma cells.
Whole-cell lysates were obtained from human U937, T98G and U251MG
cells treated for 3 days with vehicle or 17a-AED (10mM). A 30mg weight of
total protein from these cells were subjected to Western blot analysis, and
probed with an Ab specific for the total caspase 3 or PARP. A reduced
level of pro-caspase 3 or PARP, accompanied by the presence of their
smaller cleavage products can be seen 17a-AED-treated U937 cells as
compared to cells treated with vehicle, but not in treated malignant glioma
cells. An anti-b-actin mAb was used to show equal protein loading.
M M
ABC
Figure 6 Cytopathology of T98G cells exposed to vehicle or 17a-AED (10mM) for 30h. (A) T98G cultures treated with vehicle are composed of cells
with epithelioid morphology; a large, pale staining nucleus with prominent nucleoli. A T98G cell undergoing mitosis (M). (B, C) Numerous cells in the 17a-
AED-treated cultures show the presence of multiple cytoplasmic vacuoles (arrows) and small, basophilic bodies (arrow heads). Haematoxylin and eosin
staining,  100 magnification with oil.
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sand, in the case of glioma cells, evoke cytopathological changes
consistent with autophagy.
The results of the proliferation studies showed that there is a
significant difference in the potency of the four androstene neuro-
steroids. The percentage of growth inhibition for 17a-AED at 50mM
dose was well above 80% for all of the tumours, clearly indicating
that 17a-AED is the most effective inhibitor of tumour cell
proliferation of the androstene steroids tested. In contrast, 17b-
AED, which is chemically identical, only marginally inhibited
proliferation at this concentration; therefore nonspecificity is not
an issue. The IC50 for 17a-AED is o20mM for the glioblastoma and
the lymphoma cells. This is particularly noteworthy when one
considers that the IC50 of temozolomide on malignant glioma cell
cultures has been reported to be 100mM or greater (Sankar et al,
1999; Kanzawa et al, 2003a, 2004). In addition, investigations by
Yoshida et al (2003) on the antiproliferative action of DHEA on
human cancer cell lines demonstrated that DHEA at 100mM could
inhibit B50% of Hep G2 hepatoma cell proliferation and 30% of
Caco-2 colonic adenocarcinoma cell proliferation; however, there
was no significant reduction in tumour cell viability when DHEA
was used at this dose. Also in this study, the investigators showed
that etiocholanolone, a metabolite of DHEA; had the most potent
cytotoxic activity, with an IC50 of B80mM on Hep G2 cells. This is
approximately 10 times less potent than that of the cytotoxic
effects of 17a-AED on human U937 lymphoma and T98G
malignant glioma cells.
When used at high concentrations, 17b-AED, 7a-AET and 7b-
AET were able to inhibit proliferation of the tumour cells, although
the degree of inhibition was marginal as compared to that of 17a-
AED. In terms of chemical structure, these results are interesting
because 17a-AED and 17b-AED are chemically identical but differ
in the placement, that is, above or below the plane of the
androstene molecule, of a hydroxyl on the seventeenth carbon and
yet exhibit an extreme difference their capacity to inhibit tumour
cell proliferation. Furthermore, the addition of a hydroxyl group at
the seventh position in either a or b orientation on the 17b-AED
molecule does not increase the antiproliferative effects of 17b-
AED. Overall, the results of the proliferation studies suggest that
the potency of the antiproliferative effects of the androstenes may
be dependent upon the placement and the number of the hydroxyl
groups on the tetra-cyclic, androstene molecule.
Subsequent studies demonstrated that morphological effects
could be noted on glioblastoma cultures after 18h of exposure to
17a-AED, which included disruption of the cell monolayer and
decreased adherence to the tissue culture plate. Also at this time
point, reduced cell viability could be detected in the treated
tumour cell cultures. The induction of cell death by 17a-AED were
not as pronounced on U251MG cells, as compared with the T98G
and U937 cells, suggesting that the U251MG cells may be more
resistant to this neuro-steroid. Based on our previous work
showing the effects of 17a-AED in human myeloid leukaemic cell
lines, it is apparent that the effectiveness of this molecule is target
cell dependent (Huynh and Loria, 1997). This is confirmed in this
experiment.
Previous studies from our group have shown that 17a-AED
treatment induces apoptosis in human breast and leukaemic
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Figure 7 Acridine orange staining of 17a-AED-treated tumour cells indicates a high level of acidic vacuoles in T98G glioma cells, but not in U937
lymphoma cells. (A) Treatment with 10mM of 17a-AED (middle) induces a high level of AVO formation in T98G cells as compared to T98G cells treated
with vehicle (left). The presence of bafilomycin A1 (baf., 50nM) inhibits 17a-AED (10mM)-induced AVO formation in T98G cells (right). (B) A low level of
acidic vacuoles can be detected in U937 cells treated with 10mM 17a-AED (right) as compared to sham-treated cells (left). Annotated numbers indicate the
percentage of cells positive for acidic vacuoles, quadrant Q2. Representative results of at least three independent experiments are shown.
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scancer cells, as demonstrated by TUNEL and electron microscopy
(Huynh and Loria, 1997; Huynh et al, 2000). However, it does not
appear that apoptosis plays a major role in the death of malignant
glioma cells treated with 17a-AED as shown by the nominal degree
of DNA fragmentation; lack of caspase 3 cleavage and PARP
cleavage as compared to sham-treated glioma cells. Additionally,
preliminary electron microscopic analysis of the ultrastructure of
T98G glioblastoma cells treated 3 days with 17a-AED did not reveal
classical apoptotic features such as blebbing of the plasma
membrane and DNA condensation (Graf et al, unpublished
results). In some CNS diseases involving neuronal cell death, such
as amyotrophic lateral sclerosis and Huntington’s disease, tradi-
tional apoptotic features are not present (Dal Canto and Gurney,
1994; Turmaine et al, 2000).
Cytopathology revealed novel morphological changes in T98G
cells treated for 30h with 17a-AED. Most notable was the presence
of numerous, large vacuoles in the cytoplasm of the treated cells,
which was often accompanied with small, basophilic bodies.
Acridine orange staining of 17a-AED-treated cells demonstrated
that a large percentage of T98G glioma cells, but not U937
lymphoma cells, contain acidic vacuoles, and that their formation
could be inhibited with bafilomycin A1.
Two forms of programmed cell death have been recently
proposed (Bursch et al, 2000). Common features of type I
programmed cell death, also referred to as apoptosis, include
caspase activation, chromatin condensation and DNA cleavage
(Jaattela, 2002). In contrast, autophagy is a form of type II
programmed cell death, which is caspase independent, includes the
formation of AVOs and may proceed in the absence of DNA
cleavage (Lefranc and Kiss, 2006). Recent studies of human
malignant glioma cells treated with temozolomide or arsenic
trioxide have revealed that cell death occurs not by apoptosis, but
rather by the induction of autophagy (Kanzawa et al, 2004, 2004).
In our studies, human malignant glioma cells exposed to 17a-AED
displayed features characteristic of autophagy, the presence of
AVO and the ability of bafilomycin A1 to inhibit AVO formation,
but not of apoptosis. Therefore, it is possible that the antiglioma
effects of this neuro-steroid may be mediated by autophagic, type
II programmed cell death. Biochemical and genetic studies are in
progress to identify the extent to which 17a-AED induces
autophagic cell death in the glioma cells, and to determine the
molecular mechanisms involved. However, this is the first report of
the antiglioma effects of 17a-AED.
To summarize, we have demonstrated that, of the androstene
neuro-steroids tested, 17a-AED is the most potent inhibitor of
human malignant glioma cells and lymphoma cells, with an IC50
in the rage of 10 to 20mM. In fact, 17a-AED used at a concentration
of 25mM, can inhibit tumour cell proliferation by 80% or greater.
These findings indicate that the cytotoxic effects of the neuro-
steroids are dependent on the number and position of the
hydroxyl groups on the androstene molecules as well as the
aetiology of the tumour. It is apparent that the cytotoxic activity
of 17a-AED on lymphoma cells is mediated by apoptosis;
however, in malignant gliomas, it is likely that a nonapoptotic
pathway of programmed cell death is utilized, such as autophagy.
17a-AED may have clinical relevancy in the treatment of brain
tumour patients, because it is a neuro-steroid that can readily
cross the blood brain barrier and possesses potent antiglioma
activity.
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